As of 2025-11-08, the Intrinsic Value of Viking Therapeutics Inc (VKTX) is -10.56 USD. This VKTX valuation is based on the model Peter Lynch Fair Value. With the current market price of 36.77 USD, the upside of Viking Therapeutics Inc is -128.71%.
Based on its market price of 36.77 USD and our intrinsic valuation, Viking Therapeutics Inc (VKTX) is overvalued by 128.71%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -10.56 - -10.56 | -10.56 | -128.71% |
| P/E | (26.35) - (37.33) | (32.83) | -189.3% |
| DDM - Stable | (11.69) - (43.53) | (27.61) | -175.1% |
| DDM - Multi | (0.47) - (1.40) | (0.71) | -101.9% |
| Market Cap (mil) | 4,134.42 |
| Beta | 0.98 |
| Outstanding shares (mil) | 112.44 |
| Enterprise Value (mil) | 4,034.04 |
| Market risk premium | 4.60% |
| Cost of Equity | 12.50% |
| Cost of Debt | 5.00% |
| WACC | 8.09% |